- Home
- MREO
as 07-26-2024 4:00pm EST
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 550.1M | IPO Year: | N/A |
| Target Price: | $7.50 | AVG Volume (30 days): | 845.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $4.50 | Next Earning Date: | 09-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 60.82% | Revenue Growth (next year): | 4.40% |
Stock Insider Trading Activity of Mereo BioPharma Group plc (MREO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lewicki John A. | MREO | Chief Scientific Officer | Jun 25 '24 | Sell | $3.39 | 16,808 | $57,032.91 | 48,779 | SEC Form 4 |
| Lewicki John A. | MREO | Chief Scientific Officer | Jun 25 '24 | Sell | $3.69 | 7,416 | $27,393.96 | 65,587 | SEC Form 4 |
| Sermon Charles | MREO | General Counsel | Jun 25 '24 | Sell | $3.69 | 14,202 | $52,460.77 | 216,574 | SEC Form 4 |
| Sermon Charles | MREO | General Counsel | Jun 25 '24 | Sell | $3.39 | 32,187 | $109,216.93 | 184,387 | SEC Form 4 |
| Fox Christine Ann | MREO | Chief Financial Officer | Jun 25 '24 | Sell | $3.69 | 12,990 | $47,983.76 | 87,010 | SEC Form 4 |
| Fox Christine Ann | MREO | Chief Financial Officer | Jun 25 '24 | Sell | $3.39 | 29,439 | $99,892.41 | 57,571 | SEC Form 4 |
| Scots-Knight Denise | MREO | Chief Executive Officer | Jun 25 '24 | Sell | $3.69 | 40,712 | $150,386.06 | 801,791 | SEC Form 4 |
| Scots-Knight Denise | MREO | Chief Executive Officer | Jun 25 '24 | Sell | $3.39 | 92,273 | $313,100.74 | 709,518 | SEC Form 4 |
| Hughes-Wilson Alexandra | MREO | See Remarks | Jun 25 '24 | Sell | $3.69 | 10,134 | $37,433.98 | 57,516 | SEC Form 4 |
| Hughes-Wilson Alexandra | MREO | See Remarks | Jun 25 '24 | Sell | $3.39 | 22,968 | $77,935.02 | 34,548 | SEC Form 4 |
| Hughes-Wilson Alexandra | MREO | See Remarks | May 22 '24 | Sell | $2.99 | 50,350 | $150,546.50 | 58,633 | SEC Form 4 |
| Hughes-Wilson Alexandra | MREO | See Remarks | May 22 '24 | Sell | $2.94 | 50,082 | $147,241.08 | 32,568 | SEC Form 4 |
Latest Mereo BioPharma Group plc News
MREO Breaking Stock News: Dive into MREO Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 07/01/2024
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/28/2024
Investing.com
a month ago
Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount
MT Newswires
a month ago
Mereo BioPharma Prices $50 Million Offering
GlobeNewswire
a month ago
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
MT Newswires
a month ago
Update: Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate
Zacks
a month ago
Ultragenyx (RARE) Posts New Data From Bone Disease Study
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise Premarket Wednesday
Compare MREO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MREO Mereo BioPharma Group plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.